Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling
British Journal of Clinical Pharmacology · 2026-06 · 92 (6) · 1845-1856
DOI: 10.1002/bcp.70443 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 26.01.2026. Verfasst von Hoang Dat Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Master of Science Program in Biopharmaceutical Sciences, Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Linezolid, Rifampin, Models, Biological, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Aims
The study aims to develop a physiologically‐based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP‐binding cassette sub‐family B member 1 ( ABCB1 ) and ATP‐binding cassette super‐family G member 2 ( ABCG2 ) in the drug–drug interaction (DDI) between rifampin and linezolid and to predict the impact of high‐dose rifampin on linezolid pharmacokinetics (PK).
Methods
We developed a PBPK model of linezolid and verified this using published clinical PK data. The built‐in PK‐SIM PBPK model for rifampin was used as a perpetrator model, which incorporate ABCB1 and ABCG2 transporter activity, along with inhibition and induction kinetic parameters. Using the developed PBPK models, linezolid PK was predicted when co‐administered with rifampin and verified using published data. Based on the developed DDI model, linezolid exposure when co‐administered with high‐dose rifampin at steady state was predicted.
Results
The developed linezolid PBPK model had acceptable predictive performance for 36 different PK arms from 13 individual clinical studies. The PBPK‐predicted DDI effect of standard dose rifampin on linezolid, with AUC and C max ratios of 0.77 and 0.87, respectively, aligned well with observed DDI ratio. PBPK simulations indicated that both ABCG2 and ABCB1 contributed to the DDI between linezolid and rifampin, with ABCB1 playing the major role in the interaction. Increasing the daily dose of rifampin from 10 mg/kg to 20–40 mg/kg resulted in a similar linezolid exposure.
Conclusions
Our study suggested that ABCB1 is the primary transporter responsible for the interaction between rifampin and linezolid. The DDI effect of high‐dose rifampin on linezolid plasma exposure is similar to that of standard‐dose rifampin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Master of Science Program in Biopharmaceutical Sciences, Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
- Department of Pharmacology and Pharmacogenomics Research Center, Inje University, College of Medicine, Busan, Republic of Korea.
- Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
- Infectious Diseases Data Observatory, University of Oxford, Oxford, UK.
ORCID-Profile: Hoang Dat Nguyen, Joel Tarning
Förderung
- Wellcome Trust
Zitieren
APA
Nguyen, H. D., Pham, V. H., Hoglund, R. M., Tarning, J., & Ding, J. (2026). Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 92(6), 1845-1856. https://doi.org/10.1002/bcp.70443
Vancouver
Nguyen HD, Pham VH, Hoglund RM, Tarning J, Ding J. Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling. British Journal of Clinical Pharmacology. 2026;92(6):1845-1856. doi:10.1002/bcp.70443
BibTeX
@article{Nguyen2026,
author = {Nguyen, Hoang Dat and Pham, Vinh Hoa and Hoglund, Richard M and Tarning, Joel and Ding, Junjie},
title = {Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {6},
pages = {1845--1856},
doi = {10.1002/bcp.70443}
}
EUVIMED